Tumor necrosis factor superfamily ligands (TNF)

TNF-α-IN-1 is a TNF-α inhibitor extracted from patent US20030096841A1, compound example I-7.Form:SolidIC50&amp Target:TNF-α

TNF-α-IN-1 is a TNF-α inhibitor extracted from patent US20030096841A1, compound example I-7.IC50&amp Target:TNF-α

TNF-α-IN-2 is a potent and orally active inhibitor of tumor necrosis factor alpha (TNFα) , with an IC 50 of 25 nM in the HTRF assay. TNF-α-IN-2 distorts the TNFα trimer upon binding, leading to aberrant signaling when the trimer binds to TNFR1.

TNF-α-IN-2 is a potent and orally active inhibitor of tumor necrosis factor alpha (TNFα) , with an IC 50 of 25 nM in the HTRF assay. TNF-α-IN-2 distorts the TNFα trimer upon binding, leading to aberrant signaling when the trimer binds to TNFR1.

TNF-α-IN-6 is an orally efficacious allosteric inhibitor of TNFα ( K D = 6.8 nM).Form:Solid

TNF-α-IN-6 is an orally efficacious allosteric inhibitor of TNFα ( K D = 6.8 nM).Form:Solid

TNF-α-IN-6 is an orally efficacious allosteric inhibitor of TNFα ( K D = 6.8 nM).Form:Solid

Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling.

Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling.

Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling.

tumour necrosis factor membrane form

tumour necrosis factor membrane form